Insilico Medicine nominated ISM5059, a peripheral‑restricted NLRP3 inhibitor, as a preclinical candidate developed with generative AI, while Phylo raised $13.5 million to commercialize Biomni Lab, an AI‑enabled integrated biology environment for research automation. Both moves highlight momentum for software-driven design and lab automation across discovery and preclinical development. Insilico’s nomination demonstrates a closed-loop AI-to‑chemistry workflow reaching candidate status, emphasizing in silico design plus experimental validation. Phylo’s capital raise—led by top-tier VCs and built on an open-source foundation—targets productivity gains for bench scientists and high-throughput bioinformatics workflows. These developments point to two complementary investment themes: AI-generated molecule design progressing into IND-enabling work, and infrastructure that embeds AI into everyday lab operations. Biotech R&D leaders should expect increased adoption of agentic platforms and more AI-originated IND candidates coming into the clinic.